CA
NZ
UK
AU
IND
US
FDA Orphan Drug Designation Expands Scope in Pediatric Brain Cancer TreatmentPlus Therapeutics has secured U.S. FDA Orphan Drug Designation for REYOBIQ, its investigational radiotherapeutic targeting pediatric malignant gliomas. Notably, the designation extends beyond the company’s initial request to include pediatric ependymoma, broadening the potential …
iBio, Inc. has taken a notable step in its development trajectory with regulatory clearance in Australia to initiate a first-in-human Phase 1 trial for IBIO-600. The Clinical Trial Notification acknowledgement from the Therapeutic Goods Administration, alongside ethics approval, enables the company to begin dosing …
UroGen Pharma Expands Clinical Engagement in LG-UTUC Treatment LandscapeUroGen Pharma Ltd. has introduced its “LG-UTUC Luminaries” initiative, a clinician- and institution-focused program aimed at advancing care standards for low-grade upper tract urothelial cancer (LG-UTUC). The initiative underscores the company’s broader strategy of embedding itself …
Single-Patient Case Study Highlights Early Signal for Phyto-N in Cancer CachexiaCuranex Pharmaceuticals drew market attention after presenting a single-patient case study suggesting potential symptomatic benefits of its lead candidate, Phyto-N, in cancer cachexia and advanced cancer supportive care. The patient, treated for a pancreatic …
BioXcel Therapeutics has initiated patient enrollment in a Phase 2a clinical trial evaluating BXCL501 for acute stress reactions (ASR), marking a notable step in the company’s effort to expand its neuroscience pipeline. The study, funded by the U.S. Department of War and led by …
AI Nose Healthcare Deployment Signals Strategic Expansion into High-Value InfrastructureAinos, Inc. (NASDAQ: AIMD) has announced a partnership with MacKay Memorial Hospital and Topco Scientific to deploy its AI Nose technology across critical hospital environments. This move marks a notable extension of its Smell AI …
PMGC Holdings’ full utilization of its $20 million equity purchase facility with Streeterville Capital marks a notable step in reinforcing its balance sheet. The transaction provides incremental liquidity to support near-term acquisitions and integration efforts, while signaling management’s intent to actively deploy capital across …
enGene Therapeutics Name Change Reflects Commercial Transition StrategyenGene’s decision to rebrand from enGene Holdings Inc. to enGene Therapeutics Inc. marks a strategic inflection point as the company moves closer to potential commercialization. The name change, effective April 8, 2026, aligns with its evolving identity …
Cryptocurrency markets have once again demonstrated their sensitivity to global macro developments. Bitcoin’s sharp rally following news of a temporary ceasefire between the United States and Iran highlights the asset class’s growing alignment with broader risk sentiment.
Global financial markets pivoted sharply toward a risk-on stance after a temporary ceasefire agreement between the United States and Iran signaled a pause in escalating geopolitical tensions. The development marks a critical inflection point after weeks of heightened uncertainty that had driven volatility across …
Please wait processing your request...